The Vascular Endothelial Growth Factor’s Expression in Gastric Cancer and Progress in Prognostic Research

Abstract

Gastric cancer (GC) is not only one of the common gastrointestinal malignancies in clinic, but also the most common cancer in the world. In recent years, its morbidity has increased. The global morbidity and mortality of gastric cancer rank fifth among all malignancies. The morbidity and mortality of gastric cancer in our country ranks second among malignant tumors, which is twice as high as the world average. In rural, the number is 1.6 times of in urban. The early diagnosis of most gastric cancers is rare in majority of patients, and most of them are in intermediate or advanced stage when they are in treatment. The proportion of radical surgery is not high, and it is easy to relapse and metastasize. The 5-year survival rate is about 40%, and the treatment effect is poor, which is severely harmful to people’s health. Although the pathogenesis of gastric cancer is related to many factors, the nosogenesis is vague. The occurrence of tumors is closely related to the formation of new blood vessels. New blood vessels are the internal conditions for tumor cell proliferation and metastasis. The factors that promoting angiogenesis include more than 10 kinds of fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGF), among which VEGF is the most important regulator that promotes angiogenesis. By promoting the mitosis of vascular endothelial cells, it forms an essential matrix for the growth of vascular endothelial cells, plays a crucial regulatory role in the process of tumor angiogenesis, and participates in the occurrence and development of a variety of tumor cells. This article summarizes the research progress on the vascular endothelial growth factor’s expression in gastric cancer and prognostics follows.